XTX Topco Ltd Invests $330,000 in Dyne Therapeutics, Inc. (NASDAQ:DYN)

Key Points

• XTX Topco Ltd has acquired a new stake in Dyne Therapeutics, Inc., purchasing 31,574 shares valued at approximately $330,000.
• Several institutional investors, including Y Intercept Hong Kong Ltd and GSA Capital Partners LLP, have also increased their positions in Dyne Therapeutics during the 1st quarter.
• Analysts have mixed ratings on Dyne Therapeutics with a consensus rating of "Moderate Buy" and a target price of $34.94, despite recent price target reductions from several firms.

XTX Topco Ltd acquired a new stake in Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) in the 1st quarter, according to the company in its most recent filing with the SEC. The fund acquired 31,574 shares of the company's stock, valued at approximately $330,000.

Other institutional investors have also recently bought and sold shares of the company. Summit Investment Advisors Inc. grew its stake in Dyne Therapeutics by 9.1% in the fourth quarter. Summit Investment Advisors Inc. now owns 8,627 shares of the company's stock valued at $203,000 after acquiring an additional 721 shares during the period. China Universal Asset Management Co. Ltd. grew its stake in Dyne Therapeutics by 5.2% in the first quarter. China Universal Asset Management Co. Ltd. now owns 22,690 shares of the company's stock valued at $237,000 after acquiring an additional 1,115 shares during the period. Arizona State Retirement System grew its stake in Dyne Therapeutics by 9.2% in the first quarter. Arizona State Retirement System now owns 17,501 shares of the company's stock valued at $183,000 after acquiring an additional 1,481 shares during the period. GF Fund Management CO. LTD. acquired a new position in Dyne Therapeutics in the fourth quarter valued at about $50,000. Finally, GAMMA Investing LLC grew its stake in Dyne Therapeutics by 837.5% in the first quarter. GAMMA Investing LLC now owns 2,625 shares of the company's stock valued at $251,000 after acquiring an additional 2,345 shares during the period. Institutional investors own 96.68% of the company's stock.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on the company. Evercore ISI reaffirmed an "outperform" rating on shares of Dyne Therapeutics in a research report on Friday, July 11th. Oppenheimer reduced their price objective on Dyne Therapeutics from $34.00 to $13.00 and set an "outperform" rating for the company in a research report on Wednesday, August 6th. Stifel Nicolaus reduced their price objective on Dyne Therapeutics from $66.00 to $36.00 and set a "buy" rating for the company in a research report on Thursday, July 31st. HC Wainwright reduced their price objective on Dyne Therapeutics from $46.00 to $38.00 and set a "buy" rating for the company in a research report on Friday, May 9th. Finally, Robert W. Baird reduced their price objective on Dyne Therapeutics from $46.00 to $32.00 and set an "outperform" rating for the company in a research report on Wednesday, June 18th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating, thirteen have issued a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat.com, Dyne Therapeutics presently has a consensus rating of "Moderate Buy" and a consensus price target of $34.94.

Dyne Therapeutics Stock Up 1.3%

Dyne Therapeutics stock traded up $0.16 during midday trading on Thursday, reaching $12.40. The stock had a trading volume of 1,023,351 shares, compared to its average volume of 2,642,534. Dyne Therapeutics, Inc. has a 12 month low of $6.36 and a 12 month high of $47.45. The company has a market capitalization of $1.76 billion, a P/E ratio of -3.21 and a beta of 1.08. The company has a fifty day moving average price of $10.54 and a two-hundred day moving average price of $11.31. The company has a current ratio of 16.83, a quick ratio of 16.83 and a debt-to-equity ratio of 0.17.

Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last issued its earnings results on Monday, July 28th. The company reported ($0.97) EPS for the quarter, beating analysts' consensus estimates of ($0.99) by $0.02. As a group, equities analysts expect that Dyne Therapeutics, Inc. will post -3.44 EPS for the current fiscal year.

Insider Transactions at Dyne Therapeutics

In related news, CEO John Cox purchased 100,000 shares of the business's stock in a transaction on Monday, July 14th. The stock was acquired at an average price of $9.11 per share, for a total transaction of $911,000.00. Following the purchase, the chief executive officer owned 242,179 shares of the company's stock, valued at approximately $2,206,250.69. This trade represents a 70.33% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Company insiders own 14.14% of the company's stock.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.